Bosentan

American Journal of Cardiovascular Drugs

Volumn 2, Issue 5, 2002, Pages 335-342

  Prakash, Amitabh ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; CARBAMAZEPINE; CARDIAC GLYCOSIDE; CYCLOSPORIN; DARUSENTAN; DIGOXIN; DIURETIC AGENT; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; GLIBENCLAMIDE; ITRACONAZOLE; KETOCONAZOLE; OXYGEN; PHENYTOIN; PLACEBO; RIFAMPICIN; SIMVASTATIN; VASODILATOR AGENT; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; COUGHING; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; DYSPNEA; EXERCISE; FLUSHING; HEADACHE; HEART INDEX; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMIC PARAMETERS; HUMAN; LIVER DYSFUNCTION; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MEDICAL PARAMETERS; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYNCOPE; VERTIGO; WORLD HEALTH ORGANIZATION;

EID: 0036401770     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200202050-00006     Document Type: Article

References (39)

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987 Aug; 107 (2): 216-23
2. Kim NH, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther 2002 Jan; 7 (1): 9-19
3. De Backer TLM, Smedema J-P, Carlier SG. Current management of primary pulmonary hypertension. Biodrugs 2001; 15 (12): 801-17
4. Klings ES, Farber HW. Current management of primary pulmonary hypertension. Drugs 2001; 61 (13): 1945-56
5. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998 Aug 29; 352: 719-25
6. Rich S. Primary pulmonary hypertension. Fauci AS, Braunwald E, Isselbacher KJ, et al. In: Harrison's principles of internal medicine. 14th ed. New York: McGraw Hill Companies, Inc., 1998: 1466-8
7. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999; 61: 391-41
8. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Ann Rev Pharmacol Toxicol 2001; 41: 851-76
9. Kaur S, Frishman WH, Singh I, et al. Endothelin as a therapeutic target in the treatment of cardiovascular disease. Heart Dis 2001; 3 (3): 176-88
10. Dupuis J. Endothelin-receptor antagonists in pulmonary hypertension. Lancet 2001 Oct 6; 358 (9288): 1113-4
11. Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102 (19 Suppl.): 2434-40
12. Holm P. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction. Scand Cardiovasc J 1997; 31 Suppl. 46: 1-40
13. Actelion Pharmaceuticals US Inc. Tracleer (bosentan) prescribing information [online]. Available from URL: http://www.tracleer.com/tracleerbsite/default.asp [Accessed 2001]
14. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994 Jul; 270: 228-35
15. Wu-Wong JR, Dixon DB, Chiou WJ, et al. Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristics. J Pharmacol Exp Ther 1997 May; 281: 791-8
16. Wanstall JC, Kay CS, O' Donnell SR, et al. Evaluation of bosentan, pinacidil and nitroprusside on human pulmonary arteries: comparison with rat pulmonary arteries. Fundam Clin Pharmacol 1997; 11 (No. 6): 584-91
17. B receptor blockade. Circulation 1999 Jul 6; 100: 5-8
18. Chen S-J, Chen Y-F, Meng QC, et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995 Dec; 79 (6): 2122-31
19. Holm P, Liska J, Clozel M, et al. The endothelin antagonist bosentan: hemodynamic effects during normoxia and hypoxic pulmonary hypertension in pigs. J Thorac Cardiovasc Surg 1996 Oct; 112 (4): 890-7
20. Kim H, Yung GL, Marsh JJ, et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000 Apr; 15 (4): 640-8
21. Weber C, Schmitt R, Birnboeck H, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996 Aug; 60: 124-37
22. Weber C, Schmitt R, Birnboeck H, et al. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol 1999; 39: 703-14
23. Galie N, Hinderliter AL, Torbicki A, et al. Effects of oral endothelin receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary artery hypertension [abstract no. 1081-80]. J Am Coll Cardiol 2002 Mar 6; 39 (5 Suppl. A): 224A
24. Williamson DJ, Wallman LL, Jones R, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000 Jul 25; 102 (4): 411-8
25. Weber C, Gasser R, Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos 1999 Jul; 27: 810-5
26. Dingemanse J, Bodin F, Weidekamm E, et al. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol 2002 Mar; 42: 283-9
27. Dingemanse J, Schaarschmidt D, Van Giersbergen PLM. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Br J Clin Pharmacol 2002 May; 53 (5): 547P
28. van Giersbergen PLM, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 2002; 53: 589-95
29. Binet I, Wallnöfer A, Weber C, et al. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int 2000 Jan; 57 (1): 224-31
30. van Giersbergen PLM, Treiber A, Clozel M, et al. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 2002; 71: 253-62
31. Weber C, Banken L, Birnboeck H, et al. Effect of endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999 Aug; 39 (8): 847-54
32. Weber C, Banken L, Birnboeck H, et al. The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br J Clin Pharmacol 1999 Jun; 47: 701-6
33. Badesch DB, Bodin F, Channick RN, et al. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Curr Thera Res 2002 Apr; 63 (4): 227-46
34. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001 Oct 6; 358 (9288): 1119-23
35. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002 Mar 21; 346 (12): 896-903
36. Rubin LJ, Galiè N, Simonneau G. Bosentan for pulmonary hypertension [letter, reply]. N Engl J Med 2002 Jul 25; 347 (4): 293-4
37. Roux S, Kobrin I, Rainisio M, et al. Long-term open-label study in patients with pulmonary hypertension who participated in controlled clinical studies with bosentan (interim study report - protocol AC-052-354). Actelion Pharmaceuticals US, Inc., 2001 Oct 3
38. Roux S, Kobrin I, Rainisio M, et al. Open-label, long-term study in patients with pulmonary hypertension who participated in controlled clinical studies with bosentan (second interim study report - protocol AC-052-053). Actelion Pharmaceuticals US, Inc., 2001 Oct 3
39. Actelion Pharmaceuticals UK Ltd. Tracleer™ (bosentan) summary of product characteristics [online]. Available from URL: http\\www.actelion.com [Accessed 2002 Sep 16]